Marc Saad, MD
Clinical Cardiac Electrophysiology · Lafayette, LANPI 1548451677
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 54.0% of the total. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in LA, where the typical reported total is $18,132.
Across 196 payments — averaging $42.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$2K
- Medtronic$521
- Novartis$225
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
- Biotronik Inc.$165
- plus $1K from 23 others
Across 12 payments — averaging $1715.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$21K
What the payments were for
- Consulting fees$7008%
- Travel & lodging$2,86934%
- Food & beverage$4,76357%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 74 | $4,498 |
| Boston Scientific | 11 | $1,517 |
| Medtronic(2 entities) | 25 | $521 |
| Novartis | 13 | $225 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $174 |
| Biotronik Inc. | 4 | $165 |
| Philips North America LLC | 6 | $155 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Johnson & Johnson(2 entities) | 7 | $108 |
| Arbor Pharmaceuticals, Inc. | 1 | $91 |
| Acutus Medical, Inc. | 1 | $90 |
| Kestra Medical Technology Services, Inc. | 2 | $89 |
| Cardiva Medical, Inc. | 3 | $73 |
| Abiomed | 4 | $68 |
| Pfizer | 3 | $65 |
| Boehringer Ingelheim | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Atricure, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Gilead | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $18 |
| Stryker | 1 | $15 |
| Merck | 1 | $15 |
| Itamar Medical Inc | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,858
- Watchman$1,381
- Accent Pacemaker$700
- AMPLATZER$222
- ENSITE$119
- Confirm Rx$107
How this compares
$8,331 in reported general payments places this provider in the 25th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
See all clinical cardiac electrophysiology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,029 | $869,234 |
| XareltoRivaroxaban | 264 | $214,071 |
| EntrestoSacubitril/Valsartan | 246 | $204,129 |
| Repatha SureclickEvolocumab | 38 | $33,311 |
| JardianceEmpagliflozin | 33 | $26,106 |
| SotalolSotalol Hcl | 1,342 | $19,849 |
| Ranolazine ErRanolazine | 231 | $19,835 |
| Praluent PenAlirocumab | 27 | $16,846 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 76 | $16,777 |
| FarxigaDapagliflozin Propanediol | 20 | $14,594 |
| Flecainide Acetate | 383 | $12,520 |
| Metoprolol Succinate | 1,133 | $12,304 |
| MultaqDronedarone Hcl | 13 | $12,020 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 462 | $7,495 |
| PradaxaDabigatran Etexilate Mesylate | 21 | $4,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $869,2341,029 claims |
| Johnson & JohnsonXarelto | $108 | $214,071264 claims |
| NovartisEntresto | $225 | $204,129246 claims |
| Boehringer IngelheimJardiance, Pradaxa | $54 | $30,50654 claims |
| AstraZenecaFarxiga | $11 | $14,59420 claims |
| Sanofi-aventis U.S. LLCMultaq | $52 | $12,02013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
Other clinical cardiac electrophysiology in Lafayette
- Eoin DonnellanLafayette$48K
- Alvaro Manrique GarciaLafayette$22K
- Patrick WelchLafayette$8K
- William BaileyLafayette$3K
- Nassir MarroucheNew Orleans$498K
- Sammy KhatibNew Orleans$115K
- Paul LelorierNew Orleans$101K
- Adil YousufNew Orleans$101K
- Mark PolletBaton Rouge$90K
- Joshua AymondBaton Rouge$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.